Reslizumab Signal - Search

ReslizumabPharmaceutical drug

Side effects Warnings Interactions Dosage Coupons Indications Precautions Composition

It has been shown that the numbers of eosinophils in the blood and bronchial fluid can correlate with asthma severity. Reslizumab binds to IL-5 with a dissociation constant of 81 pM and inhibiting IL-5 signaling, which reduces the production and survival of eosinophils.
Reslizumab - Wikipedia
en.wikipedia.org/wiki/Reslizumab
Was this helpful?
People also ask
How is reslizumab formulated?
Each single-use vial of reslizumab is formulated as 10 mg/mL reslizumab in an aqueous solution containing 2.45 mg/mL sodium acetate trihydrate, 0.12 mg/mL glacial acetic acid, and 70 mg/mL sucrose, with a pH of 5.5. Reslizumab was first used for eosinophilic asthma in 2008.
Reslizumab - Wikipedia
en.wikipedia.org
What are the most common adverse effects of reslizumab?
Less common adverse effects include: The most common adverse effect of reslizumab was oropharyngeal (mouth and throat) pain.
Reslizumab - Wikipedia
en.wikipedia.org
Is Reslizumab a monoclonal antibody?
Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils.
Reslizumab - Wikipedia
en.wikipedia.org
How is reslizumab degraded?
Reslizumab is degraded by enzymatic proteolysis into small peptides and amino acids, as are other monoclonal antibodies. Reslizumab was initially developed by Chuan-Chu Chou at Schering-Plough and was previously known as SCH-55700.
Reslizumab - Wikipedia
en.wikipedia.org
Is Reslizumab a sterile solution?
Reslizumab is supplied as a refrigerated, sterile, single-use, preservative-free solution for intravenous infusion. The reslizumab solution is a slightly hazy/opalescent, slightly yellow liquid and is supplied as 100 mg in a 10 mL glass vial.
Reslizumab - Wikipedia
en.wikipedia.org
What is reslizumab aqueous solution?
The reslizumab solution is a slightly hazy/opalescent, slightly yellow liquid and is supplied as 100 mg in a 10 mL glass vial. Each single-use vial of reslizumab is formulated as 10 mg/mL reslizumab in an aqueous solution containing 2.45 mg/mL sodium acetate trihydrate, 0.12 mg/mL glacial acetic acid, and 70 mg/mL sucrose, with a pH of 5.5.
Reslizumab - Wikipedia
en.wikipedia.org
Feedback
National Center for Biotechnology Information
https://www.ncbi.nlm.nih.gov/books/NBK4…
Reslizumab (Cinqair) - NCBI Bookshelf - National …
Reslizumab is a humanized immunoglobulin G (IgG)4 kappa monoclonal antibody that binds to human interleukin-5, thereby reducing the production and survival of eosinophils.
Missing:

Signal
Must include:

Signal
Other content from ncbi.nlm.nih.gov
See more
SAGE Journals
https://journals.sagepub.com/doi/full/10.1177/20420986241284112
Disproportionality analysis of reslizumab based on the FDA …
Oct 7, 2024 · With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events (AEs) in clinical practice. Objectives: …
Wikipedia
https://en.wikipedia.org/wiki/Reslizumab
Reslizumab - Wikipedia
Reslizumab binds to IL-5 with a dissociation constant of 81 pM and inhibiting IL-5 signaling, which reduces the production and survival of eosinophils. However, the mechanism of reslizumab …
Missing:
- Signal
Must include:
- Signal
PubMed
https://pubmed.ncbi.nlm.nih.gov/39381062
Disproportionality analysis of reslizumab based on the FDA …
Oct 7, 2024 · While reslizumab offered a promising treatment option for severe eosinophilic asthma, more attention should be paid to the common AEs and new unexpected AEs. Based …
nih.gov
https://pmc.ncbi.nlm.nih.gov/articles/PMC8175040
Anaphylactic risk related to omalizumab, benralizumab, reslizumab ...
Omalizumab, benralizumab, reslizumab, and mepolizumab showed positive signals for anaphylaxis, while only dupilumab showed a negative signal. The risk of initial or prolonged …
National Center for Biotechnology Information
https://www.ncbi.nlm.nih.gov/books/NBK476071
EXECUTIVE SUMMARY - Reslizumab (Cinqair) - NCBI Bookshelf
Reslizumab is a humanized immunoglobulin G (IgG)4 kappa monoclonal antibody that binds to human interleukin-5, thereby reducing the production and survival of eosinophils.
Missing:
- Signal
Must include:
- Signal
BMC Pulmonary Medicine
https://bmcpulmmed.biomedcentral.com/articles/10...
Adverse events of anti-IL-5 drugs in patients with eosinophilic …
Feb 3, 2024 · Sum up, both clinical meta-analysis and post-marketing signal detection have identified potential risks for anti-IL-5 medications, including headaches, reactions at injection …
nih.gov
https://www.ncbi.nlm.nih.gov/books/NBK476086
INTRODUCTION - Reslizumab (Cinqair) - NCBI Bookshelf
Overview
Pharmacology
Medical uses
Adverse effects
History
Reslizumab is an interleukin IL-5 antagonist monoclonal antibody. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Eosinophils play a role in the mediation of inflammation in the airways. Eosinophilic asthma is a phenotype of asthma that is characterized by the higher than normal presence of eosinophils in the lung and sputum. It has been shown that the numbers of eosinophils in the blood and bronc…
Wikipedia · Text under CC-BY-SA license
Missing:
- Signal
Must include:
- Signal
drugbank.com
https://go.drugbank.com/drugs/DB06602
Reslizumab: Uses, Interactions, Mechanism of Action - DrugBank …
Mar 19, 2008 · Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non …
Missing:
- Signal
Must include:
- Signal
PubMed
https://pubmed.ncbi.nlm.nih.gov/38035014
Parasitic infections related to anti-type 2 immunity monoclonal ...
Nov 14, 2023 · The aim was to explore safety signals of parasitic infections for omalizumab, mepolizumab, reslizumab, dupilumab, and benralizumab. Methods: Spontaneous reports were …
Pagination
- 1
- 2
- 3
- 4
- Next